Relacorilant Demonstrates Sustained Efficacy in Hypertension Control for Patients with Cushing’s Syndrome: Results from the Phase 3 GRACE Study
Posted inDiabetes & Endocrinology Internal Medicine news

Relacorilant Demonstrates Sustained Efficacy in Hypertension Control for Patients with Cushing’s Syndrome: Results from the Phase 3 GRACE Study

The Phase 3 GRACE trial demonstrates that relacorilant, a selective glucocorticoid receptor modulator, significantly maintains hypertension control in patients with Cushing’s syndrome without the safety concerns associated with non-selective antagonists, such as adrenal insufficiency or hypokalemia.
Intensive Blood Pressure Targets Below 130/80 mmHg Benefit Patients Across the Cardiovascular-Kidney-Metabolic Syndrome Spectrum
Posted inCardiology Nephrology news

Intensive Blood Pressure Targets Below 130/80 mmHg Benefit Patients Across the Cardiovascular-Kidney-Metabolic Syndrome Spectrum

A post hoc analysis of the CRHCP trial demonstrates that intensive blood pressure control (<130/80 mmHg) significantly reduces major adverse **Confirming JSON Structure** I'm now fully focused on creating the JSON object. I've re-reviewed both schemas, and am following the most up-to-date and complete instructions. I'm double-checking the required fields, especially `thumbnail`, `lang`, and `multilang`, to ensure the final output is perfectly structured and valid. cardiovascular events across CKM syndrome stages 2 through 4, providing a favorable net clinical benefit despite an increased risk of hypotension.
Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial
Posted inCardiology Internal Medicine news

Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial

The ESPRIT trial reveals that targeting systolic blood pressure below 120 mmHg significantly reduces cardiovascular events across diverse populations, including frail patients and those with diabetes, while uniquely improving retinal microvascular health and maintaining patient quality of life.
Precision Hypertension Management: Haptoglobin Phenotype Predicts Cardiovascular Benefit from Intensive Blood Pressure Control in Type 2 Diabetes
Posted inCardiology Diabetes & Endocrinology news

Precision Hypertension Management: Haptoglobin Phenotype Predicts Cardiovascular Benefit from Intensive Blood Pressure Control in Type 2 Diabetes

A post-hoc analysis of the ACCORD trial reveals that intensive blood pressure control significantly reduces cardiovascular and stroke risk in haptoglobin 1 allele carriers, but not in those with the Hp2-2 phenotype, suggesting a genotype-driven approach to hypertension management in diabetes.
The Earlier, the Better: INTERACT Pooled Analysis Confirms 3-Hour Golden Window for Intensive Blood Pressure Lowering in Acute ICH
Posted inEmergency Medicine Neurology news

The Earlier, the Better: INTERACT Pooled Analysis Confirms 3-Hour Golden Window for Intensive Blood Pressure Lowering in Acute ICH

A pooled analysis of over 11,000 patients from the INTERACT trials demonstrates that intensive blood pressure reduction significantly improves functional recovery in acute intracerebral hemorrhage, with the most robust benefits observed when treatment is initiated within three hours of symptom onset.
Early-Life Famine Exposure in Chinese Immigrants Strongly Linked to Later Diabetes and Hypertension — But Not Cardiovascular Hospitalization
Posted inDiabetes & Endocrinology news Public Health

Early-Life Famine Exposure in Chinese Immigrants Strongly Linked to Later Diabetes and Hypertension — But Not Cardiovascular Hospitalization

A large Ontario cohort study links early-life exposure to the Great Chinese Famine with higher adult risks of type 2 diabetes and hypertension among Chinese immigrants, while cardiovascular hospitalization was not increased; methodological caveats underline need for age-balanced research.